BIOHEART AND AGELESS PARTNER TO ADVANCE STEM CELL FIELD WITH LABORATORY TRAINING PROGRAMS
Bioheart, Inc. (BHRT.OB) announced today that it has successfully conducted a laboratory training course in partnership with the Ageless Regenerative Institute.
BIOHEART CONSORTIUM OF DIRECTORS AND
SHAREHOLDERS PURCHASE NOTE SHOWING
CONTINUED CONFIDENCE IN COMPANY’S FUTURE
Bioheart, Inc. (BHRT.OB) announced today that NorthStar Biotech LLC, a consortium of Bioheart Directors and Shareholders, has purchased a company note in the amount of $572,000 previously held by BlueCrest Venture Finance Master Fund Limited.
BIOHEART APPOINTS ADVISORY BOARD OF BUSINESS AND FINANCIAL EXECUTIVES
Bioheart, Inc. (BHRT.OB) announced today it has appointed a five-member Advisory Board comprised of local and international business, financial and marketing executives to assist in the development of the company’s new business plan.
Bioheart Announces University of Miami as Clinical
Site for Angel Trial of AdipoCell™
Bioheart, Inc. (BHRT.OB) announced that the company will conduct the ANGEL trial using adipose (fat) derived stemcell technologyor AdipoCell™ at the University of Miami Miller School of Medicine.
Bioheart to Present at BioFlorida’s Saturday Exchange
Bioheart (BHRT.OB), a leader in developing stem cell therapies to treat cardiovascular diseases, today announced that they have been chosen as a presenter in the BioFlorida Saturday Exchange conference later this month.
Bioheart Acquires Exclusive Rights to Ageless
Regenerative Institute’s Adipose Cell Technology
Bioheart, Inc. (BHRT.OB) announced today that it has acquired the worldwide exclusive rights to Ageless Regenerative Institute’s
adipose (fat) derived therapeutic cell technology for use in the cardiac field.